Why Moderna Stock Is Rising Today
Shares of Moderna (NASDAQ: MRNA) were rising 3.3% as of 10:59 a.m. EDT on Monday. This gain came after the Financial Times reported new forecasts from health data analytics company Airfinity that project Moderna's COVID-19 vaccine could generate sales of $38.7 billion in 2022.
Investors might be justified in jumping aboard the Moderna train if Airfinity's 2022 estimate is right. Sales of $38.7 billion would give the vaccine stock a forward price-to-sales multiple of less than 3.5. That's an attractive valuation if Moderna can continue generating sales in the same ballpark going forward.
Image source: Getty Images.
Source Fool.com
